The pimary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Factors driving the growth of this market include the increasing adoption of primary cell over cell lines, increasing R&D activities for the development of new cancer therapies, and increasing collaborations & acquisitions.
The primary cells market is consolidated in nature, with a few number of players offering variety of products. The key players in the market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (US), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).
Most companies in the primary cells market adopted expansions and acquisitions as the key business growth strategy. These strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018.
Thermo Fisher Scientific (US)
Thermo Fisher Scientific held the leading position in the primary cells market in 2017. Due to its well-established product portfolio, the company maintained its leading position in the primary cells market. The company adopted acquisitions as a key strategy in order to strengthen its position as well as expand its product portfolio. For instance, in 2016, the company acquired MTI-GlobalStem (US) in order to increase and expand its primary cells portfolio.
Merck KGaA (Germany)
In 2017, Merck KGaA ranked second in the primary cells market. The company offers a wide range of products in this market. The company adopted both inorganic growth strategies in order to increase its dominance in this market. The company is highly focused on the Asia Pacific region and investments in countries like China, India, and South Korea. For instance, the company acquired Sigma-Aldrich (US) in 2015, in order to increase and expand its primary cells portfolio.
Lonza (Switzerland)
Lonza is engaged in providing chemical and biotechnology ingredients and custom manufacturing services to pharmaceutical, healthcare, and life science industries. The company operates through two divisions, namely, Specialty Ingredients and Pharma & Biotech. Through its Pharma & Biotech segment, the company offers human and animal primary cells. The company adopted product launches as a key strategy in order to strengthen its position as well as expand its product portfolio. For instance, in 2018, Lonza expanded its primary cells portfolio and added hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells to its hepatocytes portfolio.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=32854960
